The Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game Users

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers. The aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers. Participants will receive either the lubricating eyedrop first for 1 month, followed by a control condition (no eyedrops) for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Individuals with dryness symptoms as assessed with the Ocular Surface Disease Index (OSDI score ≥ 13).

• Individuals who play handheld console and computer-based games ≥ 2 hours everyday on average

• Individuals who are comfortable and competent at using smartphone applications

• Age ≥ 18 years, male or female

• Able to provide written consent in English

• Able to instil the treatment lubricating eyedrop on their own, and return any provided eyedrop bottle to the researcher used at the end of the treatment

• Able to attend multiple visits (3 visits over 2 months)

Locations
Other Locations
United Kingdom
School of Optometry, Aston University
RECRUITING
Birmingham
Contact Information
Primary
James S Wolffsohn, PhD
dryeye@aston.ac.uk
+441212044400
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 28
Treatments
Experimental: TheaLoz Duo in first month, crossover to control condition in second month
The TheaLoz Duo eyedrop will be prescribed and used by the participant for 1 month. At the second visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle, and no eyedrops will be prescribed, and the participant monitored following 1 month. At the third and final visit 1 month later, the participant will return for a follow-up visit.
Active_comparator: Control condition in first month, crossover to TheaLoz Duo in second month
No eyedrops will be prescribed and the participant monitored for 1 month. At the second visit 1 month later, the participant will return and be prescribed TheaLoz Duo eyedrop and used by the participant for another 1 month. At the third and final visit 1 month later, the participant will return the TheaLoz Duo eyedrop bottle and complete the study visits.
Related Therapeutic Areas
Sponsors
Leads: Aston University

This content was sourced from clinicaltrials.gov